Navigation Links
Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Date:12/8/2007

well-tolerated and may represent a benefit for patients in terms of convenience and ease of administration. Tanespimycin is clearly an active and manageable agent and is deserving of further clinical study."

"We continue to see meaningful antitumor activity and tolerability with the tanespimycin plus bortezomib combination in multiple myeloma across patient populations. In addition, we are observing intriguing evidence supporting the hypothesis that in the tanespimycin/bortezomib combination, tanespimycin may be exerting a neuroprotective effect based on the observation of reduced neuropathy, a side effect associated with bortezomib," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "The data from this ongoing trial are still being evaluated, and multiple patients remain on study. At this time, the overall response rate appears to be lower than previously reported. We are investigating whether there were patient characteristics that may have contributed to this lower response rate, including the possibility that patients added to the study since the data were last reported represented a more advanced and heavily pretreated population. We will complete the study and further evaluate the data in consultation with multiple myeloma experts to confirm the most expeditious course forward. Taken as a whole, the currently available data from this trial suggest that there may be utility in adjusting the TIME program to optimize the therapeutic potential of the tanespimycin and bortezomib combination. We have not, however, made any definitive decisions concerning a potential adjustment."

Tanespimycin Phase 1b Trial Results

The objective of the Phase 1b dose-escalating trial was to evaluate tanespimycin with bortezomib in patients with relapsed, refractory multiple myeloma, relative to safety, pharmacokinetic, pharmacodynamic and anti-myeloma effects. Dose escalations in the entire trial ranged from 100-340 mg/m2 for
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... LONDON , July 14, 2014  VirtualScopics, ... (AIM: IXI) jointly announced today the formation of a ... Edward Ashton , Ph.D., chief scientific officer, VirtualScopics, ... members. "The formation of this joint Scientific ... commercial and operational alliance we signed with IXICO plc ...
(Date:7/13/2014)... -- Eli Lilly and Company (NYSE: LLY ... in genetically engineered mice examining combination therapy with ... and beta-secretase inhibitor BACE (LY2811376). Data results found ... clumps of amyloid-beta protein in the brain – ... Alzheimer,s disease (AD) – than use of one ...
(Date:7/11/2014)... , July 11, 2014 Patient ... marketing and, consequently, organizations are turning to an ... As part of this evolving approach ... to educate, communicate and engage patients throughout their ... to patient empowerment. By mapping the patient journey ...
Breaking Medicine Technology:VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 2VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 3VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 4VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 5VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 6VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 7VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 8VirtualScopics, Inc. And IXICO plc Announce The Formation Of A Scientific Advisory Board To Benefit Both Companies; Dr. Edward Ashton, Ph.D. Appointed Chairman 9New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2
... Calif., April 29, 2011 First Quarter ... by 321 institutions, up from 239 in Q4 2010 ... revenue Operational focus enables lower planned expense growth in ... by Astellas NGX-1998 Phase 2 clinical trial continues in ...
... Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ), a ... cancers and infectious diseases, announced today that the company will ... Securities Research Conference San Francisco, CA, May 9-11, 2011 ... Dr. J. Joseph Kim, Ph.D., President & CEO May ...
Cached Medicine Technology:NeurogesX Reports First Quarter 2011 Results 2NeurogesX Reports First Quarter 2011 Results 3NeurogesX Reports First Quarter 2011 Results 4NeurogesX Reports First Quarter 2011 Results 5NeurogesX Reports First Quarter 2011 Results 6NeurogesX Reports First Quarter 2011 Results 7NeurogesX Reports First Quarter 2011 Results 8Inovio Pharmaceuticals to Present at Investor Conferences 2Inovio Pharmaceuticals to Present at Investor Conferences 3Inovio Pharmaceuticals to Present at Investor Conferences 4
(Date:7/14/2014)... NJ (PRWEB) July 14, 2014 ... established global leader in enterprise-class cloud management, governance, ... platforms, today announced AvePoint software will be available ... managed cloud specialist. , The hosting ... to offer the following AvePoint solutions to new ...
(Date:7/14/2014)... Washington DC (PRWEB) July 14, 2014 ... MessageSolution, an industry leader and Microsoft gold partner will ... network with Microsoft partners from the world and to ... all Microsoft platforms of Exchange email server, Office 365, ... DC from July 13 to 17, 2014. , “In ...
(Date:7/14/2014)... The Cabin Chiang Mai, Asia’s leading inpatient addiction ... website – a free comprehensive aftercare service for ... recovery wherever they live in the world. , The ... help them maintain their recovery after successfully completing primary ... treatment programme. As a chronic disease, addicts in recovery ...
(Date:7/14/2014)... According to the Blood Pressure Solution book ... that features a series of new information on high ... this book can help readers understand more about blood pressure. ... and effective methods to control hypertension naturally. ... Vkool, was penned by Ken Burge, a medical researcher and ...
(Date:7/14/2014)... CA (PRWEB) July 14, 2014 "Medical ... every one of us. The Tri-Valley is a star ... Companies based in the region are working on amazing ... changing the face of medicine," according to Dale Kaye ... , To showcase some of the brilliant minds and ...
Breaking Medicine News(10 mins):Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 2Health News:AvePoint Works with Rackspace to Extend Vital Management Features to Hybrid SharePoint Deployments 3Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 2Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 3Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 4Health News:MessageSolution to Showcase Information Archiving and eDiscovery Platform for Exchange, Office 365 and SharePoint at Microsoft Worldwide Partner Conference 2014 (WPC) 5Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 2Health News:The Cabin Chiang Mai Addiction Rehab Launches Industry-leading Aftercare Service 3Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 2Health News:Blood Pressure Solution Book Review Exposes Ken Burge's Hypertension Treatment Guide – Vkool.com 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 4
... Medical Center have uncovered a protein in nerve cells that ... manufacture drugs that are capable of blocking chronic pain, by ... alleviating chronic pain have focused on the "second order" neurons ... brain. It's difficult to inhibit the activity of these neurons ...
... and Social Welfare’s Health Education Unit (HEU) in Swaziland ... than 40 communities in the country. // ... get the people thinking abut HIV AIDS through documentaries. ... Public Relations Officer Nana Mdluli said the campaign would ...
... the investigators at St. Jude Children's Research Hospital it was ... gland function during nursing can also initiate leukemias. // ... and fuses with another gene. The discovery of the normal ... the activity of its mutated form might be used in ...
... age 45 years or older who experience migraines with ... are at a higher risk for heart// attack, ischemic ... compared to women who do not report a migraine ... form of migraine, was not associated with increased risk ...
... at Buffalo researchers are conducting one of the ... ,The project is expected to provide ... quality is critical, such as in health-care facilities ... guest rooms in the Buffalo Niagara Marriott in ...
... China on Saturday reported a new outbreak of bird flu ... Xinjiang.// ,The national avian influenza laboratory tested samples ... stemming from an outbreak that began on July 14 near ... ,A total of 3,045 chickens died in the outbreak, and ...
Cached Medicine News:Health News:It may be possible to switch off acute pain 2Health News:Gene Responsible For Mammary Gland Function, When Mutated Results in Leukemias 2Health News:Gene Responsible For Mammary Gland Function, When Mutated Results in Leukemias 3Health News:Migraines with Aura Associated with Increased Risk for Cardiovascular Disease 2Health News:Scientists Put "Allergy-Friendly" Hotel Rooms to the Test 2Health News:Scientists Put "Allergy-Friendly" Hotel Rooms to the Test 3
... Protection Device features the ability to use ... lesion and a pre-loaded nitinol filter with ... Offering a fully rapid exchange system, the ... the indicated applications:, Carotid Indication - ,The ...
Clot-based Assay for Anti-FXa and/or Anti-Iia Therapies...
Quantitative Plasma-based Factor XIII Incorporation Assay Kit...
Thrombin Activatable Fibrinolysis Inhibitor Assay Kit...
Medicine Products: